CasNo.92309-29-0,Imipenem-Cilastatin,(92309-29-0) Suppliers

1 Kilogram	Negotiable

Min.Order :1 Kilogram
Purity: USP/EP/BP
Payment Terms : L/C,T/T,Other

Keywords

Imipenem-Cilastatin sodium hydrate Primaxin 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,6-[(1R)-1-hydroxyethyl]-3-[[2-[(iminomethyl) amino]ethyl]thio]-7-oxo-,(5R,6S)-,mixt. with (2Z)-7-[[(2R)-2-amino-2-carboxyethyl] thio]-2-[[[(1S)-2,2-dime

Quick Details

Appearance:White crystallization
Application:antithrombotic drug
PackAge:25kg/drum
ProductionCapacity:10|Metric Ton|Day
Storage:room temperature
Transportation:AIR SEA TRAIN

Superiority:

Product Name:	Imipenem-Cilastatin sodium hydrate
Synonyms:	Primaxin;Thienam;Tienam 500;IMipeneM and Cilastatin SodiuM with SodiuM Bicarbonate;7-[(2S)-2-amino-2-carboxy-ethyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopro panecarbonyl]amino]hept-2-enoic acid: (5R)-3-[2-(aminomethylideneamino )ethylsulfanyl]-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene -2-carboxylic acid;Imipenem-Cilastatin sodium hydrate;Sodium (Z)-7-[(2R)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoate (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid hydrate;1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1R)-1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R,6S)-, mixt. with (2Z)-7-(((2R)-2-amino-2-carboxyethyl)thio)-2-((((1S)-2,2-dimethylcyclopropyl)carbonyl)amino)-2-heptenoic acid
CAS:	92309-29-0
MF:	C28H43N5O9S2
MW:	657.8
EINECS:	1592732-453-0
Product Categories:
Mol File:	92309-29-0.mol

Imipenem-Cilastatin sodium hydrate Usage And Synthesis

Clinical Use	Antibacterial agent
Drug interactions	Potentially hazardous interactions with other drugs Antiepileptics: reduced valproate concentration - avoid. Antivirals: convulsions reported with concomitant administration of ganciclovir and valganciclovir. Ciclosporin: variable reports of increase / no change in ciclosporin levels, and of neurotoxicity.
Metabolism	When administered alone, imipenem is metabolised in the kidneys by dehydropeptidase-I, an enzyme in the brush border of the renal tubules, to inactive, nephrotoxic metabolites, with only about 5 to 40 or 45% of a dose excreted in the urine as unchanged active drug. Cilastin inhibits the metabolism of imipenem. When given with cilastatin about 70% of an intravenous dose of imipenem is recovered unchanged in the urine within 10 hours. Cilastatin is also excreted mainly in the urine, the majority as unchanged drug and about 12% as N-acetyl cilastatin. Less than 1% of imipenem is excreted via the bile in the faeces.